Should You Buy Tvardi Therapeutics Inc (TVRD) Today? Analysis, Price Targets, and 2026 Outlook.
Conclusion
Hold
Latest Price
3.900
1 Day change
-3.94%
52 Week Range
43.650
Analysis Updated At
2026/01/26
Tvardi Therapeutics Inc (TVRD) does not present a strong buy opportunity for a beginner long-term investor at this time. The stock is currently in a pre-market decline (-8.10%), with no significant positive catalysts or trading signals. Financial performance remains weak, with negative net income and a sharp drop in EPS (-72.43% YoY). While options data indicates low put-call ratios, suggesting some bullish sentiment, the lack of news, weak technical indicators, and absence of significant trading trends make this stock unsuitable for immediate investment.
Technical Analysis
The MACD is slightly positive (0.115) but contracting, RSI is neutral at 61.42, and moving averages are converging, indicating no clear trend. The stock is trading near its pivot level (4.505) with key resistance at 4.841 and support at 4.169. Pre-market price is down 8.10%, suggesting bearish sentiment.
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
The low put-call ratios indicate some bullish sentiment, but overall option volume is low, with only 20 call contracts traded today.
Technical Summary
Sell
10
Buy
4
Positive Catalysts
Low put-call ratios in options data suggest some bullish sentiment. Historical volatility is high, which could attract speculative interest.
Neutral/Negative Catalysts
Pre-market price drop of -8.10%. Weak financial performance with negative net income and a significant drop in EPS (-72.43% YoY). No recent news or significant trading trends from hedge funds, insiders, or Congress.
Financial Performance
In Q3 2025, the company reported no revenue growth (0% YoY), a net income loss of -$5,527,000 (up 0.25% YoY), and a sharp EPS decline to -0.59 (-72.43% YoY). Gross margin remains at 0%.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
No analyst rating or price target data available for TVRD.
Wall Street analysts forecast TVRD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TVRD is 9 USD with a low forecast of 4 USD and a high forecast of 15 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
Wall Street analysts forecast TVRD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TVRD is 9 USD with a low forecast of 4 USD and a high forecast of 15 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
4 Hold
0 Sell
Moderate Buy
Current: 4.060
Low
4
Averages
9
High
15
Current: 4.060
Low
4
Averages
9
High
15
Raymond James
Outperform -> Market Perform
downgrade
AI Analysis
2025-10-14
Reason
Raymond James
Price Target
AI Analysis
2025-10-14
downgrade
Outperform -> Market Perform
Reason
Raymond James downgraded Tvardi Therapeutics to Market Perform from Outperform without a price target. The firm believes many open questions remain regarding TTI-101 following the unsuccessful REVERT-IPF readout. The discontinuation rate seen in the readout adds risk to this program, the analyst tells investors in a research note. Raymond James downgraded Tvardi to reflect the removal of the idiopathic pulmonary fibrosis opportunity and uncertainty on the path forward.
Raymond James
Outperform
initiated
$62
2025-07-14
Reason
Raymond James
Price Target
$62
2025-07-14
initiated
Outperform
Reason
Raymond James initiated coverage of Tvardi Therapeutics with an Outperform rating and $62 price target. The company is developing TTI-101 in idiopathic pulmonary fibrosis, an indication where blockbuster antifibrotics "have left plenty of room for improvement," the analyst tells investors in a research note. The firm believes TTI-101's clinical efficacy and safety profile so far provides strong therapeutic evidence.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for TVRD
